Skip to content

Genetic and Environmental Risk Assessment for Colorectal Cancer in Healthy Participants

Providing Genetic And Environmental Cancer Risk Assessment In Primary Care

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00087360
Enrollment
Unknown
Registered
2004-07-12
Start date
2003-11-30
Completion date
2007-05-31
Last updated
2013-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

colon cancer, rectal cancer

Brief summary

RATIONALE: Evaluating the knowledge and attitudes of healthy participants toward a new diet and gene test for colorectal cancer risk may help doctors improve acceptance of colorectal cancer screening. PURPOSE: This clinical trial is studying the knowledge and attitudes of healthy participants toward genetic and environmental risk assessment for colorectal cancer.

Detailed description

OBJECTIVES: Part 1 * Determine the willingness of healthy participants to enroll in a genetic and environmental risk assessment for colorectal cancer. * Determine the impact of decision counseling on knowledge and attitudes about genetic and environmental risk assessment (GERA) and colorectal cancer screening in these participants. * Determine participants' understanding of GERA. * Determine participants' response to GERA results. Part 2 * Determine awareness of, and interest in, diet and genetic assessment for colorectal cancer among healthy participants at average risk for colorectal cancer who have not undergone regular colon cancer screening. * Determine participants' level of knowledge of this assessment. * Determine participants' rate of acceptance into this study. OUTLINE: This is a 2-part pilot study. * Part 1: Participants complete a baseline questionnaire on attitudes, beliefs, and knowledge about colorectal cancer (CRC), CRC screening, and diet and genetic testing for colorectal cancer risk. Two-four weeks later, participants are educated about CRC screening options and undergo genetic and environmental risk assessment (GERA) decision counseling about the methylene tetrahydrofolate reductase (MTHFR) gene and dietary folate intake. Participants who decide to undergo GERA undergo blood testing for MTHFR polymorphisms and folate levels. Participants whose blood tests indicate low folate levels are further counseled about dietary folate intake. * Part 2: Participants complete a questionnaire on attitudes, beliefs, and knowledge about CRC, CRC screening, and diet and genetic testing for colorectal cancer risk. Participants in part 1 are followed at 1 week, 1 month, and then at 6 months. PROJECTED ACCRUAL: A total of 110 participants (60 for part 1 and 50 for part 2) will be accrued for this study.

Interventions

OTHERcounseling intervention
OTHERphysiologic testing
PROCEDUREevaluation of cancer risk factors

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Fox Chase Cancer Center
Lead SponsorOTHER

Study design

Primary purpose
SCREENING

Eligibility

Sex/Gender
ALL
Age
50 Years to 74 Years
Healthy volunteers
Yes

Inclusion criteria

DISEASE CHARACTERISTICS: * Healthy participants * Eligible for colorectal cancer screening * No personal or family history of colorectal cancer * No more than 1 first-degree relative who has had colorectal cancer * Part 1: * Has not undergone regular screening for colorectal cancer * Part 2: * Not currently undergoing regular colon cancer testing, including any of the following: * Fecal occult blood testing within the past year * Flexible sigmoidoscopy or colonoscopy within the past 5 years PATIENT CHARACTERISTICS: Age * 50 to 74 Performance status * Not specified Life expectancy * Not specified Hematopoietic * Not specified Hepatic * Not specified Renal * Not specified Other * No inflammatory bowel disease (part 1 only) * No concurrent health issues that would preclude study participation (part 1 only) * No history of cancer except basal cell or squamous cell skin cancer (part 2 only) * Able to speak and read English (part 2 only) PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified

Design outcomes

Primary

MeasureTime frame
Colorectal cancer (CRC) screening rates by chart review at 4 months

Secondary

MeasureTime frame
Knowledge regarding CRC risk by questionnaires at 4 and 12 months
CRC risk perception by questionnaires at 4 and 12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026